Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Technology Advances: CISH technology Facilitates Assay of HER2 Expression
Dorothy J. Schirf, MD, MDLinx Oncology
Today's Oncology News: VEGFb Designated Orphan Drug Status By FDA
D Scott Cunningham MD, PhD, MDLinx Oncology
  See all
breast cancer risk; HER2 codon 655 polymorphism Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis
Breast Cancer Research and Treatment, 05/16/08
Print     Email This Article     Save in My Library   Free Abstract
Tao W et al. - in a study to evaluate the association between HER2 codon 655 polymorphism and breast cancer risk, it was shown that HER2 codon 655 Val allele is weakly associated with an increased risk of breast cancer, and SNP at HER2 codon 655 could be considered a susceptibility biomarker for breast cancer for Asian females or women age 45 years or younger

Methods
  • A search was performed to identify all case–control studies investigating such association
  • Statistical analyses were conducted with software MIX 1.54
  • 20 eligible reports, including 10,642 cases/11,259 controls, were identified

Results
  • Overall, the Val allele frequency in cases was significantly higher than that in controls, while no associations were found in both recessive and dominant models
  • In subgroup analysis, HER2 codon 655 polymorphism was weakly associated with breast cancer risk in recessive, dominant, and co-dominant genetic models in Asian population, respectively
  • The susceptibility to breast cancer in people aged <=45 was significantly increased in both recessive and dominant models
  • No significant associations were observed in Caucasian, European, and family history subgroups

 

--- BASIC SCIENCE/GENETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- BREAST TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.